(UroToday.com) The American Society for Radiation Oncology’s 2021 annual meeting included an educational session discussing multidisciplinary management of very high-risk prostate cancer and a presentation by Dr. Ronald Chen highlighting radiation therapy for very high-risk to oligometastatic prostate cancer. Dr. Chen notes that among high-risk prostate cancer patients, two trials (NCIC PR.3 and SPCG-7) showed an improvement in overall survival comparing lifelong ADT versus ADT + radiotherapy: